Your browser is no longer supported. Please, upgrade your browser.
JAZZ Jazz Pharmaceuticals plc weekly Stock Chart
JAZZ [NASD]
Jazz Pharmaceuticals plc
Index- P/E35.84 EPS (ttm)4.55 Insider Own2.50% Shs Outstand61.19M Perf Week-1.69%
Market Cap9.98B Forward P/E10.93 EPS next Y14.91 Insider Trans-4.09% Shs Float58.91M Perf Month-6.44%
Income278.90M PEG2.29 EPS next Q3.32 Inst Own96.70% Short Float3.18% Perf Quarter-11.00%
Sales1.79B P/S5.56 EPS this Y-15.40% Inst Trans4.48% Short Ratio3.63 Perf Half Y6.04%
Book/sh47.69 P/B3.42 EPS next Y13.70% ROA8.40% Target Price195.24 Perf Year7.84%
Cash/sh13.32 P/C12.24 EPS next 5Y15.67% ROE16.00% 52W Range128.58 - 184.00 Perf YTD21.08%
Dividend- P/FCF19.01 EPS past 5Y4.60% ROI9.80% 52W High-11.40% Beta1.06
Dividend %- Quick Ratio3.60 Sales past 5Y22.50% Gross Margin93.00% 52W Low26.79% ATR3.16
Employees1210 Current Ratio3.80 Sales Q/Q26.90% Oper. Margin26.10% RSI (14)32.73 Volatility1.85% 1.82%
OptionableYes Debt/Eq0.55 EPS Q/Q-12.50% Profit Margin24.20% Rel Volume0.76 Prev Close161.93
ShortableYes LT Debt/Eq0.54 EarningsAug 07 AMC Payout0.00% Avg Volume516.42K Price163.03
Recom2.00 SMA20-3.07% SMA50-5.63% SMA2003.04% Volume391,891 Change0.68%
Aug-08-18Reiterated Stifel Buy $180 → $205
Jul-11-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-23-18Reiterated H.C. Wainwright Neutral $150 → $160
Mar-19-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-03-18Initiated Leerink Partners Outperform $180
Dec-05-17Reiterated Mizuho Neutral $144 → $150
Nov-10-17Resumed H.C. Wainwright Neutral $150
Nov-08-17Reiterated RBC Capital Mkts Outperform $210 → $195
Oct-19-17Initiated FBR & Co. Buy $206
Oct-05-17Initiated Morgan Stanley Equal-Weight $155
Sep-28-17Initiated Goldman Neutral $165
Aug-25-17Initiated H.C. Wainwright Neutral $144
May-31-17Reiterated Mizuho Neutral $150 → $144
May-15-17Initiated RBC Capital Mkts Outperform $210
Apr-06-17Downgrade Mizuho Buy → Neutral $162 → $150
Mar-21-17Reiterated Mizuho Buy $152 → $162
Feb-21-17Reiterated Mizuho Buy $127 → $152
Nov-09-16Reiterated Mizuho Buy $185 → $127
Aug-10-16Reiterated Mizuho Buy $195 → $185
Jul-19-16Reiterated Mizuho Buy $193 → $195
Sep-17-18 02:46PM  The Week Ahead: Alibaba Investor Day, FedEx Earnings, Eventbrite IPO Benzinga
Sep-11-18 04:05PM  Jazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch PR Newswire
Sep-06-18 10:28AM  Why Is Jazz (JAZZ) Down 2.4% Since Last Earnings Report? Zacks
Aug-30-18 10:35AM  Is Jazz Pharmaceuticals plcs (NASDAQ:JAZZ) PE Ratio A Signal To Buy For Investors? Simply Wall St.
Aug-29-18 04:05PM  Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences PR Newswire
Aug-27-18 09:27AM  Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe Zacks
02:00AM  Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia PR Newswire
Aug-21-18 10:41AM  5 Low-Cost Biotech Stocks With High Levels of Growth InvestorPlace
Aug-20-18 10:03AM  8 Undervalued Biotech Stocks to Watch InvestorPlace
Aug-17-18 07:45AM  Edited Transcript of JAZZ earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-13-18 04:48PM  All that Jazz: Growing pharmaceutical company opens new Philadelphia office American City Business Journals
04:05PM  These Five 95+ Composite Rating Stocks Are Just Below Buy Points Investor's Business Daily
Aug-09-18 10:15AM  7 Biotech Stocks With Big Upcoming Catalysts Kiplinger
Aug-08-18 10:21AM  Stocks Fall As Trade War Heats Up; This Top Growth Stock Breaks Out Investor's Business Daily
08:45AM  Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat Zacks
Aug-07-18 05:35PM  Jazz: 2Q Earnings Snapshot Associated Press
05:01PM  IBD 50 Stock Jazz Pharma Tops Views, But Profit Outlook Light Investor's Business Daily
04:05PM  Jazz Pharmaceuticals Announces Second Quarter 2018 Financial Results PR Newswire
02:30PM  11 Blue Chips Drive Dow Jones Higher; How Apple Can Hit $1.25 Trillion In Market Cap Investor's Business Daily
02:30PM  Jazz Pharmaceuticals Plc to Host Earnings Call ACCESSWIRE
Aug-06-18 04:15PM  Jazz Pharmaceuticals and MD Anderson Cancer Center Collaborate to Evaluate Potential Treatment Options for Hematologic Malignancies PR Newswire
09:38AM  Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store? Zacks
08:38AM  Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ) Zacks
Aug-03-18 08:00AM  CMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection PR Newswire
Jul-31-18 04:14PM  IBD Stock Of The Day: Jazz Pharma Approaches Buy Point Ahead Of Earnings Investor's Business Daily
Jul-24-18 04:05PM  Jazz Pharmaceuticals to Report 2018 Second Quarter Financial Results on August 7, 2018 PR Newswire
Jul-19-18 04:45PM  Journal of Clinical Oncology publishes pivotal Phase 3 data for Jazz Pharmaceuticals' Vyxeos® (daunorubicin and cytarabine) Liposome for Injection PR Newswire
Jul-18-18 07:20AM  Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks ACCESSWIRE
Jul-13-18 01:53PM  U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents Reuters
09:57AM  U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug Reuters
Jul-11-18 03:25PM  Morgan Stanley Downgrades Jazz Pharmaceuticals As Stock Approaches Price Target Benzinga
Jul-09-18 02:00PM  5 Low Price-to-Book Stocks Worth Buying in July InvestorPlace
Jul-06-18 02:36PM  Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval Zacks
10:34AM  Aclaris Stock Up on JAK Inhibitor's Encouraging Activity Zacks
Jul-02-18 10:34AM  Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics Zacks
Jun-29-18 04:05PM  Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt PR Newswire
10:01AM  5 Stocks Near 52-Week High: Is More Upside in the Cards? Zacks
08:15AM  Vyxeos Receives Positive CHMP Opinion for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia PR Newswire
Jun-28-18 10:51AM  Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review Zacks
Jun-27-18 04:15PM  Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients PR Newswire
Jun-26-18 12:02PM  Innoviva And Other Great Growth Stocks Simply Wall St.
Jun-25-18 10:31AM  Is Jazz Pharmaceuticals plcs (NASDAQ:JAZZ) Balance Sheet A Threat To Its Future? Simply Wall St.
Jun-19-18 08:55AM  5 Low-Beta Stocks to Buy as Trade Conflict Intensifies Zacks
Jun-18-18 07:32AM  Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA Zacks
Jun-15-18 10:03AM  5 Stocks Near 52-Week High With More Room to Run Zacks
09:23AM  5 Best Bargain PEG Stocks That Value Investors Love Zacks
07:09AM  Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar ACCESSWIRE
Jun-07-18 08:41AM  Jazz Pharmaceuticals (JAZZ) Up 16.9% Since Earnings Report: Can It Continue? Zacks
Jun-06-18 04:05PM  Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference PR Newswire
04:03PM  Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln Reuters
Jun-04-18 08:20AM  Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open Text, and ChemoCentryx New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jun-03-18 05:00PM  Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea PR Newswire
05:00PM  Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy PR Newswire
May-31-18 08:30AM  New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea PR Newswire
May-24-18 04:05PM  Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS PR Newswire
May-22-18 03:09PM  Jazz Securities Designated Activity Company -- Moody's assigns Ba1 to Jazz Pharma's senior secured credit facilities Moody's
06:31AM  3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists Motley Fool
May-14-18 07:10AM  Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks ACCESSWIRE
May-13-18 11:51PM  Edited Transcript of JAZZ earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 08:30AM  Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting PR Newswire
May-09-18 04:05PM  Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences PR Newswire +5.93%
10:32AM  Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates Zacks
06:00AM  3 Top Biotech Stocks to Buy in May Motley Fool
May-08-18 08:53PM  Jazz Pharmaceuticals to settle U.S. probe for $57 million Reuters
07:39PM  Jazz: 1Q Earnings Snapshot Associated Press
06:24PM  Jazz Pharmaceuticals Sets Aside $57 Million to Settle DOJ Probe Bloomberg
04:05PM  Jazz Pharmaceuticals Announces First Quarter 2018 Financial Results PR Newswire
May-07-18 08:30AM  Drug/Biotech Q1 Earnings Lineup on May 8: JAZZ, ARNA & More Zacks
May-02-18 11:17AM  Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store? Zacks
May-01-18 08:30AM  Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients PR Newswire
Apr-30-18 05:27PM  Peninsula drug maker swings $110 million deal for voucher American City Business Journals
09:18AM  Voucher sale brings $110M payday for Spark Therapeutics American City Business Journals
Apr-24-18 04:05PM  Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018 PR Newswire
Apr-09-18 07:50AM  Research Report Identifies Yirendai, Atlantic Capital Bancshares, Jazz Pharmaceuticals, Sina, Akebia Therapeutics, and SMART Global with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-19-18 09:37AM  Jazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A Potential Benzinga
Mar-16-18 09:35AM  Should Value Investors Pick Jazz Pharmaceuticals (JAZZ) Stock? Zacks
Mar-14-18 07:35AM  New Research: Key Drivers of Growth for Jazz Pharmaceuticals, Armstrong World Industries, Banco Latinoamericano de Comercio Exterior, S.A, Mercury, Canadian National Railway, and Bank of Nova Scotia Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-07-18 02:31PM  Why Biotech Stocks Face Steep Declines Ahead Investopedia
Mar-06-18 04:05PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March PR Newswire
Mar-02-18 08:30AM  Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea PR Newswire
Feb-28-18 08:16PM  Edited Transcript of JAZZ earnings conference call or presentation 27-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
09:29AM  Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y Zacks
Feb-27-18 07:59PM  Jazz misses Street 4Q forecasts Associated Press
05:45PM  Jazz Pharma's Fourth-Quarter Sales, Profit Lag; Guidance Mixed Investor's Business Daily
04:05PM  Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results PR Newswire
12:20PM  Jazz Pharmaceuticals Plc to Host Earnings Call ACCESSWIRE
11:33AM  Jazz Pharmaceuticals Q4 Earnings Outlook Benzinga
07:00AM  Wired News - Jazz Pharma Enrolled First Patient in Phase-2 Clinical Trial Assessing Defibrotide for the Prevention of Acute Graft-versus-Host Disease ACCESSWIRE
Feb-25-18 03:50PM  The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
Feb-23-18 08:30AM  Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease PR Newswire
Feb-21-18 10:30AM  Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect? Zacks
Feb-19-18 12:21PM  Interested In Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ)? Heres What Its Recent Performance Looks Like Simply Wall St.
Feb-13-18 04:05PM  Jazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018 PR Newswire
Feb-12-18 03:50PM  Why ImmunoGen Jumped Higher Today Motley Fool
Feb-08-18 04:15PM  National Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology PR Newswire
Jan-15-18 03:10PM  Concert Pharmaceuticals Plunges on Patent Petition Setback Zacks
Jan-12-18 08:05AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Jan-05-18 07:35AM  How Jazzs Erwinaze, Defitelio, and Prialt Performed in 3Q17 Market Realist
Jan-04-18 12:20PM  How Is Jazz Pharmaceuticals Xyrem Positioned after 3Q17? Market Realist
10:50AM  How Did Jazz Pharmaceuticals Perform in 3Q17? Market Realist
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Young Matthew P.EVP & CFOSep 17Sale162.70700113,89033,468Sep 19 05:05 PM
MILLER MICHAEL PATRICKEVP, US CommercialSep 14Sale165.2020033,04025,372Sep 17 06:06 PM
ENRIGHT PATRICK GDirectorSep 06Option Exercise139.1010,1301,409,09426,599Sep 07 04:30 PM
ENRIGHT PATRICK GDirectorSep 06Sale168.7610,1301,709,56516,469Sep 07 04:30 PM
Young Matthew P.EVP & CFOAug 15Sale176.05700123,23534,168Aug 16 06:57 PM
MILLER MICHAEL PATRICKEVP, US CommercialAug 14Sale175.7020035,14025,572Aug 16 04:52 PM
Treacy PaulSVP, Technical OperationsAug 10Sale176.611,309231,18317,458Aug 13 07:03 PM
BERNS PAUL LDirectorAug 10Sale176.61660116,5636,772Aug 13 06:52 PM
Gray PeterDirectorAug 10Sale176.61715126,2778,182Aug 13 06:47 PM
O'Keefe Kenneth WDirectorAug 10Sale176.61660116,5634,450Aug 13 06:42 PM
McSharry Heather AnnDirectorAug 10Sale176.61715126,2767,504Aug 13 06:38 PM
Schnee ElmarDirectorAug 10Sale176.61742131,0456,094Aug 13 06:23 PM
Sohn Catherine A.DirectorAug 10Sale176.61660116,5637,654Aug 13 06:20 PM
ENRIGHT PATRICK GDirectorAug 10Sale175.131,365239,05716,469Aug 13 06:13 PM
Winningham Rick EDirectorAug 10Sale176.61660116,5634,950Aug 13 06:05 PM
RIEDEL NORBERT GDirectorAug 10Sale176.61660116,5636,491Aug 13 07:57 PM
Winningham Rick EDirectorAug 09Option Exercise64.309,000578,65520,094Aug 13 06:05 PM
Winningham Rick EDirectorAug 09Sale176.1615,9792,814,8385,610Aug 13 06:05 PM
COZADD BRUCE CChairman & CEOAug 01Sale173.901,600278,240282,515Aug 03 06:21 PM
Young Matthew P.EVP & CFOJul 16Sale176.06700123,24234,868Jul 18 05:06 PM
MILLER MICHAEL PATRICKEVP, US CommercialJul 13Sale179.1520035,83025,772Jul 17 04:44 PM
COZADD BRUCE CChairman & CEOJul 02Sale170.811,600273,296284,115Jul 05 04:33 PM
Young Matthew P.EVP & CFOJun 15Sale176.99700123,89335,568Jun 19 04:26 PM
MILLER MICHAEL PATRICKEVP, US CommercialJun 14Sale176.5320035,30625,972Jun 18 04:37 PM
Young Matthew P.EVP & CFOJun 01Option Exercise58.725,000293,60041,268Jun 05 06:52 PM
Young Matthew P.EVP & CFOJun 01Sale170.045,000850,21236,268Jun 05 06:52 PM
COZADD BRUCE CChairman & CEOJun 01Sale168.867,0001,182,040285,715Jun 05 06:50 PM
Young Matthew P.EVP & CFOMay 15Sale164.641,420233,78936,203May 16 04:54 PM
MILLER MICHAEL PATRICKEVP, US CommercialMay 14Sale164.6820032,93626,122May 15 05:24 PM
WILSON KAREN JSVP, Finance & PAOMay 11Sale165.003,760620,40015,757May 15 05:27 PM
COZADD BRUCE CChairman & CEOMay 01Sale151.571,000151,570292,542May 03 04:57 PM
Young Matthew P.EVP & CFOApr 16Sale156.01700109,20738,465Apr 18 05:09 PM
MILLER MICHAEL PATRICKEVP, US CommercialApr 13Sale157.4920031,49827,481Apr 13 05:22 PM
WILSON KAREN JSVP, Finance & PAOApr 10Sale155.003,899604,34519,517Apr 12 04:25 PM
COZADD BRUCE CChairman & CEOApr 02Sale150.011,000150,010293,542Apr 04 05:49 PM
Young Matthew P.EVP & CFOMar 15Sale151.22700105,85439,165Mar 19 04:44 PM
MILLER MICHAEL PATRICKEVP, US CommercialMar 14Sale151.1220030,22427,681Mar 16 05:10 PM
COZADD BRUCE CChairman & CEOMar 09Sale150.001,000150,000294,542Mar 13 05:27 PM
Treacy PaulSVP, Technical OperationsMar 06Sale141.4759484,03018,641Mar 07 04:10 PM
Young Matthew P.EVP & CFOMar 06Sale142.361,152163,99839,865Mar 07 04:10 PM
Treacy PaulSVP, Technical OperationsMar 02Sale139.62877122,44619,235Mar 05 04:39 PM
Young Matthew P.EVP & CFOFeb 28Sale148.821,219181,41132,965Feb 28 05:57 PM
COZADD BRUCE CChairman & CEOFeb 28Sale150.001,000150,000262,830Feb 28 05:24 PM
Young Matthew P.EVP & CFOFeb 27Sale145.601,916278,96934,790Feb 28 05:57 PM
MILLER MICHAEL PATRICKEVP, US CommercialFeb 14Sale139.9920027,99821,469Feb 16 05:31 PM
Young Matthew P.EVP & CFOJan 16Sale152.16700106,51238,959Jan 18 05:05 PM
MILLER MICHAEL PATRICKEVP, US CommercialJan 12Sale148.6520029,73021,669Jan 17 04:55 PM
COZADD BRUCE CChairman & CEOJan 12Sale150.003,000450,000273,737Jan 17 04:53 PM
ENRIGHT PATRICK GDirectorDec 11Option Exercise64.309,000578,65525,339Dec 13 05:52 PM
Cox Russell J.EVP & COODec 11Option Exercise13.6350,758691,676102,821Dec 13 05:53 PM
MILLER MICHAEL PATRICKEVP, US CommercialDec 11Sale139.1520027,83021,869Dec 13 05:56 PM
ENRIGHT PATRICK GDirectorDec 11Sale139.739,0001,257,58216,339Dec 13 05:52 PM
McGill IainSVP, Europe & Rest of WorldNov 17Option Exercise46.838,000374,64028,383Nov 21 05:29 PM
McGill IainSVP, Europe & Rest of WorldNov 17Sale133.428,0001,067,35820,383Nov 21 05:29 PM
ENRIGHT PATRICK GDirectorNov 17Sale133.1935246,8831,365Nov 21 05:27 PM
COZADD BRUCE CChairman & CEOOct 02Sale150.001,000150,000276,664Oct 04 05:03 PM